 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 February 1993 | Volume 118 Issue 3 | Pages 173-178
Objective: To study the efficacy and toxicity of ganciclovir prophylaxis given at engraftment to cytomegalovirus (CMV)-seropositive, allogeneic bone marrow transplant recipients.
Design: A double-blind, placebo-controlled study.
Setting: The Fred Hutchinson Cancer Research Center, a referral marrow transplant center.
Patients: This study was conducted from November 1990 to August 1991. Ninety-three CMV-seropositive patients were entered into the study before marrow transplant, with 64 patients randomized to receive the study drug after marrow engraftment. Thirty-one patients received placebo, and 33 received ganciclovir. The dose was 5 mg/kg body weight administered intravenously twice daily for 5 days, followed by once daily until day 100 after transplant.
Measurements: Outcome variables measured were CMV infection, monitored by weekly cultures, and neutropenia, defined as an absolute neutrophil count of 0.750 x 10–9/L for 2 consecutive days. Cytomegalovirus disease and mortality were secondary end points.
Results: Fourteen (45%) placebo recipients developed CMV infection in the first 100 days after marrow transplant compared with one (3%) ganciclovir recipient (P < 0.001). Nine (29%) placebo recipients developed CMV disease compared with no cases in the ganciclovir group during the first 100 days (P < 0.001). Neutropenia occurred in 10 ganciclovir recipients (30%) compared with no cases in the placebo group during the period of observation (P = 0.001). In a separate analysis, patients on ganciclovir who became neutropenic were at greater risk (relative risk, 4.3; P = 0.02) for bacterial infection. Mortality between the two study groups did not differ statistically at 100 and 180 days.
Conclusion: Ganciclovir given prophylactically after engraftment is effective in suppressing CMV infection and disease. Neutropenia is an important side effect of ganciclovir use and is associated with an increased risk for bacterial infection.
Author and Article Information
From the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington.
ARTICLE
Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant
Deceased.
Requests for Reprints: James Goodrich, PhD, MD, The University of Texas M.D. Anderson Cancer Center, Section of Infectious Diseases (Box 47), 1515 Holcombe Boulevard, Houston, TX 77030.
Acknowledgment: The authors thank Ms. Gonzalez-White and Ms. Shirley Tyler for preparation of the manuscript.
Grant Support: Supported by grants CA 18029, CA 15704, and HL 36444 from the National Institutes of Health. Dr. Goodrich was supported in part by an award from the Poncin Scholarship Fund, Seattle, Washington.
This article has been cited by other articles:
|
|
 |
|
  D. J. Winston, J.-A. H. Young, V. Pullarkat, G. A. Papanicolaou, R. Vij, E. Vance, G. J. Alangaden, R. F. Chemaly, F. Petersen, N. Chao, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study Blood, June 1, 2008; 111(11): 5403 - 5410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) Ann. Onc., July 1, 2006; 17(7): 1051 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Einsele, P. Reusser, M. Bornhauser, P. Kalhs, G. Ehninger, H. Hebart, Y. Chalandon, N. Kroger, B. Hertenstein, F. Rohde, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation Blood, April 1, 2006; 107(7): 3002 - 3008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Wade Viral Infections in Patients with Hematological Malignancies Hematology, January 1, 2006; 2006(1): 368 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sanders, H. J. Im, P. A. Hoffmeister, T. A. Gooley, A. E. Woolfrey, P. A. Carpenter, R. G. Andrews, E. M. Bryant, and F. R. Appelbaum Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia Blood, May 1, 2005; 105(9): 3749 - 3756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Kern, D. J. Bidanset, C. B. Hartline, Z. Yan, J. Zemlicka, and D. C. Quenelle Oral Activity of a Methylenecyclopropane Analog, Cyclopropavir, in Animal Models for Cytomegalovirus Infections Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4745 - 4753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Kern, D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and D. C. Quenelle Oral Treatment of Murine Cytomegalovirus Infections with Ether Lipid Esters of Cidofovir Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3516 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Boeckh and W. G. Nichols The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy Blood, March 15, 2004; 103(6): 2003 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ljungman, R. Brand, H. Einsele, F. Frassoni, D. Niederwieser, and C. Cordonnier Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis Blood, December 15, 2003; 102(13): 4255 - 4260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Meijer, G. J. Boland, and L. F. Verdonck Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants Clin. Microbiol. Rev., October 1, 2003; 16(4): 647 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Papanicolaou, J.-B. Latouche, C. Tan, J. Dupont, J. Stiles, E. G. Pamer, and M. Sadelain Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele Blood, October 1, 2003; 102(7): 2498 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ikewaki, E. Ohtsuka, R. Kawano, M. Ogata, H. Kikuchi, and M. Nasu Real-Time PCR Assay Compared to Nested PCR and Antigenemia Assays for Detecting Cytomegalovirus Reactivation in Adult T-Cell Leukemia-Lymphoma Patients J. Clin. Microbiol., September 1, 2003; 41(9): 4382 - 4387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Radich, T. Gooley, W. Bensinger, T. Chauncey, R. Clift, M. Flowers, P. Martin, J. Slattery, D. Sultan, and F. R. Appelbaum HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen Blood, July 1, 2003; 102(1): 31 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Boeckh, W. Leisenring, S. R. Riddell, R. A. Bowden, M.-L. Huang, D. Myerson, T. Stevens-Ayers, M. E. D. Flowers, T. Cunningham, and L. Corey Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity Blood, January 15, 2003; 101(2): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Weinberg, D. Schissel, and R. Giller Molecular Methods for Cytomegalovirus Surveillance in Bone Marrow Transplant Recipients J. Clin. Microbiol., November 1, 2002; 40(11): 4203 - 4206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Tabbara, K. Zimmerman, C. Morgan, and Z. Nahleh Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results Arch Intern Med, July 22, 2002; 162(14): 1558 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Macha and A. K. Mitra Ocular Disposition of Ganciclovir and Its Monoester Prodrugs following Intravitreal Administration Using Microdialysis Drug Metab. Dispos., June 1, 2002; 30(6): 670 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berger and W. Preiser Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV J. Antimicrob. Chemother., June 1, 2002; 49(5): 713 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hebart, S. Daginik, S. Stevanovic, U. Grigoleit, A. Dobler, M. Baur, G. Rauser, C. Sinzger, G. Jahn, J. Loeffler, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma -enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation Blood, May 15, 2002; 99(10): 3830 - 3837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Woolfrey, C. Anasetti, B. Storer, K. Doney, L. A. Milner, E. L. Sievers, P. Carpenter, P. Martin, E. Petersdorf, F. R. Appelbaum, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children Blood, March 15, 2002; 99(6): 2002 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Reusser, H. Einsele, J. Lee, L. Volin, M. Rovira, D. Engelhard, J. Finke, C. Cordonnier, H. Link, and P. Ljungman Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation Blood, February 15, 2002; 99(4): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Griffiths The treatment of cytomegalovirus infection J. Antimicrob. Chemother., February 1, 2002; 49(2): 243 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gilbert, J. Roy, R. Belanger, R. Delage, C. Beliveau, C. Demers, and G. Boivin Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3669 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Griscelli, M. Barrois, S. Chauvin, S. Lastere, D. Bellet, and J.-H. Bourhis Quantification of Human Cytomegalovirus DNA in Bone Marrow Transplant Recipients by Real-Time PCR J. Clin. Microbiol., December 1, 2001; 39(12): 4362 - 4369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Solano, I. Munoz, A. Gutierrez, A. Farga, F. Prosper, J. Garcia-Conde, D. Navarro, and C. Gimeno Qualitative Plasma PCR Assay (AMPLICOR CMV Test) versus pp65 Antigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation J. Clin. Microbiol., November 1, 2001; 39(11): 3938 - 3941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Feinstein, M. Mokhtari, R. Ferreiro, D. E. Stover, and A. Jakubowski Fiberoptic Bronchoscopy in Allogeneic Bone Marrow Transplantation : Findings in the Era of Serum Cytomegalovirus Antigen Surveillance Chest, October 1, 2001; 120(4): 1094 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Szmania, A. Galloway, M. Bruorton, P. Musk, G. Aubert, A. Arthur, H. Pyle, N. Hensel, N. Ta, L. Lamb Jr, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers Blood, August 1, 2001; 98(3): 505 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Cwynarski, J. Ainsworth, M. Cobbold, S. Wagner, P. Mahendra, J. Apperley, J. Goldman, C. Craddock, and P. A. H. Moss Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation Blood, March 1, 2001; 97(5): 1232 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Nichols, L. Corey, T. Gooley, W. L. Drew, R. Miner, M.-L. Huang, C. Davis, and M. Boeckh Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes Blood, February 15, 2001; 97(4): 867 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Peggs, S. Verfuerth, and S. Mackinnon Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions Blood, February 15, 2001; 97(4): 994 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ljungman, G. L. Deliliers, U. Platzbecker, S. Matthes-Martin, A. Bacigalupo, H. Einsele, J. Ullmann, M. Musso, R. Trenschel, P. Ribaud, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients Blood, January 15, 2001; 97(2): 388 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Boivin, R. Bélanger, R. Delage, C. Béliveau, C. Demers, N. Goyette, and J. Roy Quantitative Analysis of Cytomegalovirus (CMV) Viremia Using the pp65 Antigenemia Assay and the COBAS AMPLICOR CMV MONITOR PCR Test after Blood and Marrow Allogeneic Transplantation J. Clin. Microbiol., December 1, 2000; 38(12): 4356 - 4360. [Abstract] [Full Text]
|
|
|
|
|
|
Management of herpes virus infections following transplantation J. Antimicrob. Chemother., June 1, 2000; 45(6): 729 - 748. [Full Text] [PDF]
|
|
|
|
|
|
A. E. C. Broers, R. van der Holt, J. W. J. van Esser, J.-W. Gratama, S. Henzen-Logmans, V. Kuenen-Boumeester, B. Lowenberg, and J. J. Cornelissen Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation Blood, April 1, 2000; 95(7): 2240 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Sun, K. E. Pollok, R. L. Burton, L. J. Dai, W. Britt, D. J. Emanuel, and K. G. Lucas Simultaneous Ex Vivo Expansion of Cytomegalovirus and Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes Using B-Lymphoblastoid Cell Lines Expressing Cytomegalovirus pp65 Blood, November 1, 1999; 94(9): 3242 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. W. Petersdorf, T. A. Gooley, C. Anasetti, P. J. Martin, A. G. Smith, E. M. Mickelson, A. E. Woolfrey, and J. A. Hansen Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient Blood, November 15, 1998; 92(10): 3515 - 3520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Woolfrey, T. A. Gooley, E. L. Sievers, L. A. Milner, R. G. Andrews, M. Walters, P. Hoffmeister, J. A. Hansen, C. Anasetti, E. Bryant, et al. Bone Marrow Transplantation for Children Less Than 2 Years of Age With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Blood, November 15, 1998; 92(10): 3546 - 3556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Morton, T. Gooley, J. A. Hansen, F. R. Appelbaum, B. Bruemmer, J. W. Bjerke, R. Clift, P. J. Martin, E. W. Petersdorf, J. E. Sanders, et al. Association Between Pretransplant Interferon-alpha and Outcome After Unrelated Donor Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase Blood, July 15, 1998; 92(2): 394 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Boeckh and G. Boivin Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications Clin. Microbiol. Rev., July 1, 1998; 11(3): 533 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. SULLIVAN, C. ANASETTI, M. HOROWITZ, P. A. ROWLINGS, E. W. PETERSDORF, P. J. MARTIN, R. A. CLIFT, M. C. WALTERS, T. GOOLEY, J. SIERRA, et al. Unrelated and HLA-Nonidentical Related Donor Marrow Transplantation forThalassemia and Leukemia: A Combined Report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry Ann. N.Y. Acad. Sci., June 30, 1998; 850(1): 312 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hansen, T. A. Gooley, P. J. Martin, F. Appelbaum, T. R. Chauncey, R. A. Clift, E. W. Petersdorf, J. Radich, J. E. Sanders, R. F. Storb, et al. Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia N. Engl. J. Med., April 2, 1998; 338(14): 962 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Salzberger, R. A. Bowden, R. C. Hackman, C. Davis, and M. Boeckh Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome Blood, September 15, 1997; 90(6): 2502 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Diamond, J. York, J.-Y. Sun, C. L. Wright, and S. J. Forman Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection Blood, September 1, 1997; 90(5): 1751 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Kroshus, V. R. Kshettry, K. Savik, R. John, M. I. Hertz, and R. M. Bolman III RISK FACTORS FOR THE DEVELOPMENT OF BRONCHIOLITIS OBLITERANS SYNDROME AFTER LUNG TRANSPLANTATION J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 195 - 202. [Abstract] [Full Text]
|
|
|
|
|
|
P. Reusser, R. Attenhofer, H. Hebart, C. Helg, B. Chapuis, and H. Einsele Cytomegalovirus-Specific T-Cell Immunity in Recipients of Autologous Peripheral Blood Stem Cell or Bone Marrow Transplants Blood, May 15, 1997; 89(10): 3873 - 3879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.T. Slattery, R.A. Clift, C.D. Buckner, J. Radich, B. Storer, W.I. Bensinger, E. Soll, C. Anasetti, R. Bowden, E. Bryant, et al. Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation Blood, April 15, 1997; 89(8): 3055 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Nash, T. Gooley, C. Davis, and F. R. Appelbaum The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation Oncologist, December 1, 1996; 1(6): 371 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Walter, P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor N. Engl. J. Med., October 19, 1995; 333(16): 1038 - 1044. [Abstract] [Full Text] [PDF]
|
|
Article
